Compare Merck & Co., Inc. (MRK) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Raymond James Financial, Inc. — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Raymond James Financial, Inc. trades at $158.28 (market cap $30.51B). The key difference: Merck & Co., Inc. is far larger — about 11.5× Raymond James Financial, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Raymond James Financial, Inc. for 75 Days on average.
| MRK | RJF | |
|---|---|---|
Market Cap | $351.28B | $30.51B |
Volume | 7,969,665 | 1,206,253 |
Sector | Health | Financials |
52-Week High | $156.43 | $181.18 |
52-Week Low | $82.49 | $140.89 |
Typical Hold Time | 98 Days | 75 Days |
Enterprise Value | $398.04B | $24.37B |
Dividend Yield | 2.39% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Raymond James Financial (RJF) trades at $158.60, up 0.83% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 15.37% net margins and 18.48% ROE. Recent Q3 2026 results showed record revenues of $3.93 billion, beating expectations. The company continues dividend payments with a $0.54 quarterly payout declared for October 2026.
RJF presents a mixed outlook with strong fundamental performance offset by technical weakness. The 16% upside to consensus price target of $184.00 offers potential, but investors face headwinds from rising expenses and market volatility. The absence of sell ratings and consistent institutional interest supports the investment case, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
